Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week PDUS study of secukinumab in psoriatic arthritis
2015-002394-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Secukinumab with Placebo (2 arms). Primary endpoint: Joint synovitis response (PDUS GLOESS). Started Feb 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2015-002394-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002394-38.